

**STERLING BIOTECH LIMITED**  
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30 JUNE 2010**

(Rs.in Lacs)

Sr. No.	Particulars	Quarter ended 30/06/2010	Corresponding Quarter ended 30/06/2009	SIX Months Ended 30/06/2010	Corresponding SIX Months Ended 30/06/2009	For the Year Ended 31/12/2009
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income					
	a) Net Sales/Income from Operations	39,598.22	35,763.65	77,876.47	70,721.14	143,817.29
	b) Other Operating Income	196.39	116.20	408.73	279.35	886.42
	<b>c) Total</b>	<b>39,794.61</b>	<b>35,879.85</b>	<b>78,285.20</b>	<b>71,000.49</b>	<b>144,703.71</b>
2	Expenditure					
	a) (Increase)/decrease in stock in trade and work in progress	(7,351.00)	(3,989.32)	(8,418.84)	(8,512.64)	(17,130.11)
	b) Consumption of raw materials	22,394.31	19,842.25	37,476.88	38,401.84	77,749.36
	c) Employees Cost	1,187.39	993.16	2,209.86	1,965.40	4,017.22
	d) Depreciation	4,041.96	3,006.85	7,265.81	6,013.78	12,304.21
	e) Other expenditure	7,278.91	7,272.89	14,644.54	14,065.43	28,629.32
	<b>f) Total</b>	<b>27,551.57</b>	<b>27,125.83</b>	<b>53,178.25</b>	<b>51,933.81</b>	<b>105,570.00</b>
3	Profit from Operations before Other Income and Interest (1-2)	12,243.04	8,754.02	25,106.95	19,066.68	39,133.71
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit before Interest (3+4)	12,243.04	8,754.02	25,106.95	19,066.68	39,133.71
6	Interest	5,218.43	3,113.42	10,745.97	6,107.62	14,943.77
7	<b>Profit / (Loss) from Ordinary Activities before tax (5-6)</b>	<b>7,024.61</b>	<b>5,640.60</b>	<b>14,360.98</b>	<b>12,959.06</b>	<b>24,189.94</b>
8	Tax expense					
	a) Current	1,360.00	910.00	2,570.00	1,760.00	3,500.00
	b) Deferred	950.00	400.00	2,150.00	1,800.00	3,350.00
	c) Fringe Benefit	0.00	0.00	0.00	12.50	12.50
	d) Total	2,310.00	1,310.00	4,720.00	3,572.50	6,862.50
9	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>4,714.61</b>	<b>4,330.60</b>	<b>9,640.98</b>	<b>9,386.56</b>	<b>17,327.44</b>
10	Extraordinary Items	(244.18)	(283.16)	(466.36)	(566.32)	6,205.12
11	<b>Net Profit / (Loss) for the period (9-10)</b>	<b>4,470.43</b>	<b>4,047.44</b>	<b>9,174.62</b>	<b>8,820.24</b>	<b>23,532.56</b>
12	Prior year adjustment	0.00	0.00	0.00	0.00	166.97
13	<b>Profit available for appropriation</b>	<b>4,470.43</b>	<b>4,047.44</b>	<b>9,174.62</b>	<b>8,820.24</b>	<b>23,699.53</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,501.97	2,492.32	2,501.97	2,492.32	2,501.97
15	Reserves excluding Revaluation Reserves as per balance sheet.					204,530.55
16	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.88	1.74	3.85	3.77	6.93
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.79	1.62	3.67	3.54	9.41
17	Public Shareholding					
	- Number of shares	133,666,531	132,702,208	133,666,531	132,702,208	133,666,531
	- Percentage of shareholding	53.42%	53.24%	53.42%	53.24%	53.42%
18	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	Number of shares	30,527,000	32,488,136	30,527,000	32,488,136	30,527,000
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	34.29%	36.49%	34.29%	36.49%	34.29%
	Percentage of shares (as a % of the total share capital of the Company)	12.20%	13.04%	12.20%	13.04%	12.20%
	b) Non-encumbered					
	Number of shares	58,507,694	56,546,558	58,507,694	56,546,558	58,507,694
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	65.71%	63.51%	65.71%	63.51%	65.71%
	Percentage of shares (as a % of the total share capital of the Company)	23.38%	22.69%	23.38%	22.69%	23.38%

**STERLING BIOTECH LIMITED**  
**REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021**

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30 JUNE 2010**

**Notes:**

**1 Statement of Assets and Liabilities**

(Rs. in lakhs)

Sr. No.	Particulars	SIX Months Ended 30/06/2010	Corresponding SIX Months Ended 30/06/2009
		Unaudited	Unaudited
1	<b>SHAREHOLDERS' FUNDS</b>		
	a) Capital	2,501.97	2,492.32
	b) Reserves and Surplus	213,705.16	188,450.96
2	<b>LOAN FUNDS</b>	369,374.89	274,562.39
3	Deferred Tax Liability	30,232.00	26,532.00
	<b>TOTAL</b>	<b>615,814.02</b>	<b>492,037.67</b>
4	<b>FIXED ASSETS</b>	405,665.73	326,649.82
5	<b>INVESTMENTS</b>	27,593.94	29,614.19
6	<b>CURRENT ASSETS, LOANS AND ADVANCES</b>		
	a) Inventories	67,446.25	45,708.35
	b) Sundry Debtors	58,864.75	40,065.04
	c) Cash and Bank Balances	9,316.42	6,606.93
	d) Loans and Advances	55,289.36	49,328.76
	Less: Current Liabilities and Provisions		
	a) Liabilities	6,715.70	5,996.91
	b) Provisions	2,570.00	1,772.50
7	<b>MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)</b>	923.26	1,833.99
	<b>TOTAL</b>	<b>615,814.02</b>	<b>492,037.67</b>

2 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.

3 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 7 August 2010.

4 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30 June 2010.

5 During the Quarter the Company has Repurchased / Bought Back FCCBs due 2010 of face value of USD 13.725 Million and as a result the outstanding amount of FCCBs due 2010 are reduced to USD 79.945 Million.

6 The number of investor complaints for the quarter ended on 30 June 2010 were :  
 Opening - NIL, Received - 6, Disposed off - 6, and Balance - NIL.

7 Previous period figures have been regrouped/reclassified, wherever necessary.

For and on Behalf of  
**STERLING BIOTECH LIMITED**

Place : Mumbai  
 Date : 7 August 2010.

**Joint Managing Director**